Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: An update

Autoimmunity

Volumn 45, Issue 1, 2012, Pages 111-118

  Czernik, Annette ^a   Toosi, Siavash ^b   Bystryn, Jean Claude ^b   Grando, Sergei A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptolysis; Epidermolysis bullosa acquisita; IVIg; Pemphigoid; Pemphigus; Treatment

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FC RECEPTOR; IMMUNOGLOBULIN; PARACETAMOL; PLACEBO; RITUXIMAB;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; EPIDERMOLYSIS BULLOSA ACQUISITA; HEADACHE; HUMAN; INFANTILE BULLOUS PEMPHIGOID; INFECTION; LINEAR IMMUNOGLOBULIN A DERMATOSIS; LINEAR IMMUNOGLOBULIN A DISEASE; MEDICAL RESEARCH; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; SKIN DISEASE; THROMBOEMBOLISM; TREATMENT INDICATION; URTICARIA;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 84856460385     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.606452     Document Type: Article

References (71)

1. Murrell D, Dick S, Ahmed A, Amagia M, Barnadas M, Borradori L, Bystryn J, Cianchini G, Diaz L, Fivenson D. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58(6):1043-1046.
2. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010;38(2): 186-195.
3. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006;39(7):601-607. (Pubitemid 44768929)
4. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60(4):595-603.
5. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139(8):1051-1059. (Pubitemid 36994832)
6. Harman K, Black M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases. Br J Dermatol 1999;140(5): 865-874. (Pubitemid 29238458)
7. Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001;26(2):127-131. (Pubitemid 32275702)
8. Lolis M, Toosi S, Czernick A, Bystryn J. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol 2011;64: 484-489.
9. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. New Engl J Med 2006; 355(17):1772-1779. (Pubitemid 44631360)
10. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B. A single cycle of rituximab for the treatment of severe pemphigus. New Engl J Med 2007;357(6):545-552. (Pubitemid 47236279)
11. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004;51(5):817-819. (Pubitemid 39516904)
12. Czernik A, Beutner E, Bystryn J. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008;58(5):796-801. (Pubitemid 351509651)
13. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134(4):465-469. (Pubitemid 28207630)
14. Ahmed A. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45(6):825-835. (Pubitemid 33096620)
15. Sami N, Ali S, Bhol K, Ahmed A. Influence of intravenous immunoglobulin therapy on autoantibody titres to BPAg1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003;17(6):641-645. (Pubitemid 37428084)
16. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data. J Am Acad Dermatol 2001;44(1):83-88. (Pubitemid 32110567)
17. Czernik A, Bystryn J. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: Marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008;144(5): 658-661. (Pubitemid 351724428)
18. Godard W, Roujeau J, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985;103(6 Part 1):964-965.
19. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: Therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989;20(4):684-685. (Pubitemid 19091273)
20. Beckers R, Brand A, Vermeer B, Boom B. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: Experience in six patients. Br J Dermatol 1995;133(2):289-293.
21. Xiao T, Li B,Wang YK, HeCD, ChenHD. Childhood bullous pemphigoid treated by iv immunoglobulin. J Dermatol 2007; 34(9):650-653. (Pubitemid 47313257)
22. Sugawara N, Nagai Y, Matsushima Y, Aoyama K, Ishikawa O. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy. J Am Acad Dermatol 2007;57(6): 1084-1089. (Pubitemid 350087348)
23. Urcelay M, McQueen A, Douglas W. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997;137(3):477-478. (Pubitemid 27421592)
24. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: Effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001;137(9):1181-1189. (Pubitemid 32847840)
25. Sami N, Letko E, Androudi S, Daoud Y, Foster C, Ahmed A. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: A long-term follow-up. Ophthalmology 2004;111(7):1380-1382. (Pubitemid 38844838)
26. Foster C, Ahmed A. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: A preliminary study. Ophthalmology 1999;106(11):2136- 2143. (Pubitemid 30194237)
27. Segura S, Iranzo P, Pablo IM, Mascaró JM, Jr, Alsina M, Herrero J, Herrero C. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: Evaluation of its use in 19 cases. J Am Acad Dermatol 2007;56(6):960-967. (Pubitemid 46720202)
28. Lagos J, Kemp S, Marshall G. Intravenous immune globulin in the treatment of ocular-cicatricial pemphigoid. J Allergy Clin Immunol 2007;119(Suppl. 1):S60.
29. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004;111(3):303-310. (Pubitemid 38739324)
30. Mignogna MD, Leuci S, Piscopo R, Bonovolontà G. Intravenous immunoglobulins and mucous membrane pemphigoid. Ophthalmology 2008;115(4):752.
31. Leverkus M, Georgi M, Nie Z, Hashimoto T, Bröcker EB, Zillikens D. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: Beneficial effect of adjuvant therapy with highdose intravenous immunoglobulin. J Am Acad Dermatol 2002;46(1):116-122. (Pubitemid 34073489)
32. Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002;102(1):59-67. (Pubitemid 34095225)
33. Sami N, Bhol K, Ahmed A. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long term follow up: Influence of treatment on antibody titres to human 6 integrin. Clin Exp Immunol 2002;129(3):533-540. (Pubitemid 35024924)
34. Uchino Y, Takahashi S, Uchino M, Shimazaki J. Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid. Br Med J 2007;91(1):117-118. (Pubitemid 46094023)
35. Galdos M, Etxebarr?́a J. Intravenous immunoglobulin therapy for refractory ocular cicatricial pemphigoid: Case report. Cornea 2008;27(8):967-969.
36. Iaccheri B, Roque M, Fiore T, Papadaki T, Mathew B, Baltatzis S, Emara B, Tokarewicz A, Foster CS. Ocular cicatricial pemphigoid, keratomycosis, and intravenous immunoglobulin therapy. Cornea 2004;23(8):819-822. (Pubitemid 39447313)
37. Gürcan H, Ahmed A. Intravenous immunoglobulin treatment in laryngeal pemphigoid. Clin Exp Dermatol 2009;34(8): 884-886.
38. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: A preliminary report. Ophthalmology 2010;117(5):861-869.
39. Ross A, Jaycock P, Cook S, Dick A, Tole D. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br Med J 2009;93(4):421-422.
40. Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M. Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab. Acta Derm Venereol 2009; 89(1):101-102.
41. Taverna J, Lerner A, Bhawan J, Demierre M. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007;6(7):731-732.
42. Schmidt E, Seitz C, Benoit S, Bröcker E, Goebeler M. Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol 2007;156(2):352-356. (Pubitemid 46095965)
43. Campos M, Silvente C, Lecona M, Suárez R, Lázaro P. Epidermolysis bullosa acquisita: Diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin. Clin Exp Dermatol 2006;31(1): 71-73.
44. Tayal U, Burton J, Dash C, Wojnarowska F, Chapel H. Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita. Clin Immunol 2008;129(3):518-519.
45. Caldwell J, Yancey K, Engler R, JamesW, Meier F, Sonnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa aquisita: Efficacy of high-dose intravenous immunoglobulins. Author's reply. J Am Acad Dermatol 1994;31(5): 827-828. (Pubitemid 24340768)
46. Meier F, Sönnichsen K, Schaumburg-Lever G, Dopfer R, Rassner G. Epidermolysis bullosa acquisita: Efficacy of highdose intravenous immunoglobulins. J Am Acad Dermatol 1993;29(2):334-337. (Pubitemid 23221938)
47. Mohr C, Sunderkötter C, Hildebrand A, Biel K, Rütter A, Rütter G, Luger T, Kolde G. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995;132(5):82-86.
48. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1997;36(2):331-335. (Pubitemid 27078899)
49. Gourgiotou K, Exadaktylou D, Aroni K, Rallis E, Nicolaidou E, Paraskevakou H, Katsambas A. Epidermolysis bullosa acquisita: Treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2002;16(1):77-80. (Pubitemid 34202011)
50. Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity. Br J Dermatol 2000;142(3):517-520. (Pubitemid 30159079)
51. Engineer L, Dow EC, Braverman IM, Ahmed AR. Epidermolysis bullosa acquisita and multiple myeloma* 1. J Am Acad Dermatol 2002;47(6):943-946. (Pubitemid 35403059)
52. Kroiss M, Vogt T, Landthaler M, Stolz W. High dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 2000;142(3):582. (Pubitemid 30159106)
53. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy. J Am Acad Dermatol 1999;40(3):485-488. (Pubitemid 29115315)
54. Letko E, Bhol K, Foster CS, Ahmed AR. Linear IgA bullous disease limited to the eye: A diagnostic dilemma 1: Response to intravenous immunoglobulin therapy. Ophthalmology 2000; 107(8):1524-1528.
55. Goebeler M, Seitz C, Rose C, Sitaru C, Jeschke R, Marx A, Bröcker E, Zillikens D. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol 2003;149(4):912-914. (Pubitemid 37412032)
56. Cauza K, Hinterhuber G, Sterniczky B, Brugger K, Pieczkowski F, Karlhofer F, Wolff K, Foedinger D. Unusual clinical manifestation of linear IgA dermatosis: A report of two cases* 1. J Am Acad Dermatol 2004;51(2):112-117.
57. Kreuter A, Harati A, Breuckmann F, Appelhans C, Altmeyer P. Intravenous immune globulin in the treatment of persistent pemphigoid gestationis. J Am Acad Dermatol 2004;51(6): 1027-1028. (Pubitemid 39593031)
58. Hern S, Harman K, Bhogal B, Black M. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol 1998; 23(4):185-188. (Pubitemid 28539507)
59. dos Santos Rodrigues C, Filipe P, del Mar Solana M, de Almeida LS, de Castro JC, Gomes MM. Persistent herpes gestationis treated with high-dose intravenous immunoglobulin. Acta Dermato-Venereol 2007;87(2):184-186. (Pubitemid 46513214)
60. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz L, Roopenian D, Liu Z. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005;115(12):3440-3450. (Pubitemid 43121832)
61. Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic Zlotkin M, Anhalt G, David M, Shoenfeld Y. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005;142(3): 426-432. (Pubitemid 41719837)
62. Mimouni D, BlankM, Payne A, Anhalt G, Avivi C, Barshack I, DavidM, Shoenfeld Y. Efficacy of intravenous immunoglobulin (IVIG) affinity purified anti desmoglein anti idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol 2010;162(3):543-549.
63. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat J, Tschopp J, French L. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282(5388): 490-493. (Pubitemid 28483679)
64. Orlov MD, Chernyavsky AI, Arredondo J, Grando SA. Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity 2006;39(7): 557-562. (Pubitemid 44768924)
65. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005;167(6): 1531-1544. (Pubitemid 41713308)
66. Michael D, Grando SA. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun 2008;10:333-343.
67. Pretel M, España A, Marquina M, Pelacho B, Lopez-Picazo J, Lopez-Zabalza M. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris. Exp Dermatol 2009;18(9):771-780.
68. Grando SA, Laquer VT, Le HM. Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection. J Am Acad Dermatol 2011; (in press) DOI: 10.1016/j.jaad.01.029.
69. Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int Immunopharmacol 2006;6(4): 600-606.
70. Gurcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007;41:1604-1610. (Pubitemid 47479788)
71. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6(4): 535-542.